Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SONN 
Sonnet Biotherapeutics Holdings Inc (SONN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: SONN (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $20
1 Year Target Price $20
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 34.38% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 44.24M USD | Price to earnings Ratio - | 1Y Target Price 20 |
Price to earnings Ratio - | 1Y Target Price 20 | ||
Volume (30-day avg) 1 | Beta 1.22 | 52 Weeks Range 1.08 - 10.38 | Updated Date 09/17/2025 |
52 Weeks Range 1.08 - 10.38 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.82 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1405.87% |
Management Effectiveness
Return on Assets (TTM) -223.8% | Return on Equity (TTM) -714.97% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 37571070 | Price to Sales(TTM) 44.24 |
Enterprise Value 37571070 | Price to Sales(TTM) 44.24 | ||
Enterprise Value to Revenue 37.57 | Enterprise Value to EBITDA -0.21 | Shares Outstanding 6827350 | Shares Floating 6719027 |
Shares Outstanding 6827350 | Shares Floating 6719027 | ||
Percent Insiders 4.4 | Percent Institutions 5.56 |
Upturn AI SWOT
Sonnet Biotherapeutics Holdings Inc
Company Overview
History and Background
Sonnet Biotherapeutics Holdings Inc. is a biotechnology company focused on developing innovative targeted biologic drugs for oncology. Founded in 2011, it has focused on developing Fully Human Albumin Binding (FHAB) technology.
Core Business Areas
- Oncology Therapeutics Development: Focuses on developing novel therapeutics to treat various types of cancer.
- Fully Human Albumin Binding (FHAB) Technology: Developing and utilizing their proprietary FHAB technology to improve the pharmacokinetic and pharmacodynamic profiles of therapeutic molecules.
Leadership and Structure
The leadership team includes Pankaj Mohan, Ph.D., as CEO. The organizational structure is typical of a biotechnology company, with departments focused on research and development, clinical trials, and business development.
Top Products and Market Share
Key Offerings
- SON-1010: A IL-12-FHAB fusion protein in Phase 1 development for solid tumors. Market share is currently 0%, being in clinical stages. Competitors include companies developing IL-12 therapies and other immuno-oncology drugs.
- SON-080: A Fully Human Albumin Binding-linked human Relaxin agonist in Phase 1b/2a clinical trial for treatment of platinum-resistant ovarian cancer. Market share is currently 0%. Competitors include companies developing ovarian cancer therapeutics.
Market Dynamics
Industry Overview
The oncology therapeutics market is a large and rapidly growing market, driven by increasing cancer incidence and advancements in treatment options. Immuno-oncology is a key area of growth.
Positioning
Sonnet Biotherapeutics is a clinical-stage biotechnology company focusing on immuno-oncology with their FHAB technology. Their competitive advantage lies in their targeted approach and potential for improved drug delivery and efficacy.
Total Addressable Market (TAM)
The global oncology market is estimated to be worth hundreds of billions of dollars. Sonnet is targeting niche segments within this market, leveraging its targeted therapeutic technology.
Upturn SWOT Analysis
Strengths
- Proprietary FHAB technology
- Targeted therapeutic approach
- Experienced management team
- Focus on immuno-oncology
Weaknesses
- Limited financial resources
- Early-stage pipeline
- Dependence on clinical trial success
- Small market capitalization
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Positive clinical trial results
- Increased investor interest in immuno-oncology
Threats
- Competition from larger pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Economic downturn
Competitors and Market Share
Key Competitors
- MRNA
- PFE
- BMY
Competitive Landscape
Sonnet is a small player in a competitive market dominated by large pharmaceutical companies. Their FHAB technology offers a potential competitive advantage, but requires successful clinical validation.
Growth Trajectory and Initiatives
Historical Growth: N/A - As a development-stage company, historical revenue growth is not applicable.
Future Projections: Future growth depends heavily on the success of its clinical trials and partnerships. Analyst estimates are speculative at this stage.
Recent Initiatives: Focusing on advancing its clinical trials, exploring partnerships, and securing funding.
Summary
Sonnet Biotherapeutics is an early-stage biotechnology company with promising FHAB technology. Its success hinges on advancing its clinical trials and securing partnerships. The company faces significant challenges, including limited financial resources and competition from larger players, however, their focus on immuno-oncology is in line with key industry trends.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (where available)
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. The data is based on publicly available information and may be subject to change. Investing in biotechnology companies involves significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sonnet Biotherapeutics Holdings Inc
Exchange NASDAQ | Headquaters Princeton, NJ, United States | ||
IPO Launch date 2006-10-31 | Interim CEO & Director Mr. Raghu Rao | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://www.sonnetbio.com |
Full time employees 13 | Website https://www.sonnetbio.com | ||
Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 to treat chemotherapy-induced peripheral neuropathy (CIPN), and diabetic peripheral neuropathy; SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer; SON-1411, a bifunctional combination of human interleukin 18 (IL-18) inhibitor binding protein and single-chain human IL-12 (IL-12) for solid tumor cancers; and SON-1400, a monofunctional fusion protein comprising the IL-18 binding protein resistant domain linked to the FHAB. It has a license agreement with New Life Therapeutics Pte, Ltd. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.